Heron Therapeutics | HRTX - Gross Profit On Sales

Stock Price
1.20
Daily Change
-0.08 -5.91%
Monthly
-19.80%
Yearly
-28.01%
Q1 Forecast
2.71

Heron Therapeutics reported $23.35M in Gross Profit on Sales for its fiscal quarter ending in September of 2024.





Gross Profit On Sales Change Date
ALKERMES USD 265.83M 8.06M Sep/2025
Alnylam Pharmaceuticals USD 1.05B 418.14M Sep/2025
Amarin USD 22.21M 28.15M Sep/2025
ANI Pharmaceuticals USD 111.79M 1.68M Sep/2025
Anika Therapeutics USD 14.68M 9.46M Mar/2025
Arrowhead Research USD 256.47M 228.7M Sep/2025
Eisai JPY 168.85B 17.02B Dec/2025
Esperion Therapeutics USD -29.52M 32.4M Sep/2024
GlaxoSmithKline GBP 6.18B 106M Dec/2025
Heron Therapeutics USD 23.35M 1.6M Sep/2024
Insmed USD 111.44M 33.36M Sep/2025
Ligand Pharmaceuticals USD 155.28M 82.42M Sep/2025
Merck USD 13.42B 431M Sep/2025
Nektar Therapeutics USD 13.75M 650K Jun/2024
Neurocrine Biosciences USD 780.9M 104.7M Sep/2025
Omeros USD -33.16M 18.52M Jun/2024
Pacira USD 130.92M 5M Sep/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sangamo BioSciences -2.39M 1.09M Jun/2024
Surmodics USD -11.54M 3.99M Sep/2024
Ultragenyx Pharmaceutical USD 131.94M 11.55M Sep/2025
Veracyte USD 91.28M 1.51M Sep/2025
Vertex Pharmaceuticals USD 2.66B 104.4M Sep/2025